secwatch / observer
8-K filed September 18, 2023, 7:59 PM ET ticker ISCO CIK 0001355790
debt confidence high sentiment neutral materiality 0.45

International Stem Cell CORP (ISCO): debt financing — International Stem Cell extends $2.9M CEO loan maturity to Sept 2024

International Stem Cell CORP

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

International Stem Cell CORP incurred loan of $2,900,000 with Dr. Andrey Semechkin at four and a half percent (4.5%) per annum maturing September 15, 2024.

Instrument
loan
Principal
$2,900,000
Counterparty
Dr. Andrey Semechkin
Rate
four and a half percent (4.5%) per annum
Maturity
September 15, 2024
Event
incurrence
Exact text from the filing
On September 15, 2023, International Stem Cell Corporation (the "Company") and Dr. Andrey Semechkin agreed to extend (until September 15, 2024) the maturity date of the loan (in the principal amount of $2,900,000) from Dr. Semechkin to the Company that had been reflected in a promissory note dated March 15, 2023 (the "Original Note"), and which would have been due on September 15, 2023.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

International Stem Cell CORP entered into Note with Dr. Andrey Semechkin valued at principal amount of $2,900,000 (effective 2023-09-15).

Action
entry
Counterparty
Dr. Andrey Semechkin
Value
principal amount of $2,900,000
Effective
2023-09-15
Exact text from the filing
On September 15, 2023, International Stem Cell Corporation (the “Company”) and Dr. Andrey Semechkin agreed to extend (until September 15, 2024) the maturity date of the loan (in the principal amount of $2,900,000) from Dr. Semechkin to the Company that had been reflected in a promissory note dated March 15, 2023 (the “Original Note”), and which would have been due on September 15, 2023. In exchange for the Original Note, the Company issued to Dr. Semechkin an unsecured, non-convertible promissory note in the principal amount of $2,900,000 (the “Note”) with the extended maturity date.
View on SEC.gov

Browse all debt financings →

International Stem Cell CORP filing history →

Source: SEC EDGAR
accession 0001683168-23-006510
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.